The FDA has approved the injection of Risperdal Consta (risperidone long-acting injection, from Janssen) into the deltoid muscle of the arm for the treatment of schizophrenia. This approval was based on clinical studies demonstrating similar safety, tolerability, and bioequivalence of deltoid and gluteal injections. Risperdal Consta was previously approved for gluteal injection only.

Risperdal Consta dose packs containing two separate, non-interchangeable needles for either gluteal or deltoid injection will be available by the end of 2008.

For more information call (800) 526-7736 or visit www.RisperdalConsta.com.